구조모아 (StructureMoa)항암 chemical structure spider web
방문argenx
분석
큐레이션 브리핑
경쟁 포지션: First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
기전. Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FcRn (neonatal Fc receptor)
Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy
US, EU, JP
Approved
vyvgart · efgartigimod · Vyvgart · Vyvgart Hytrulo · ARGX-113 · efgartigimod alfa-fcab
2026-09-10
Data Confidence · High
Development Signal · Established
Engineered human IgG1 Fc fragment
ABDEG mutations give high-affinity, pH-independent FcRn binding that outcompetes endogenous IgG
Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression.
구조화 데이터
Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression.
Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal.
Engineered human IgG1 Fc fragment
FcRn (neonatal Fc receptor) · Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores.
Headache, infection, and injection-site reactions; monitor for hypersensitivity
First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
AChR-antibody-positive gMG; adults with CIDP
After acetylcholinesterase inhibitors and steroids/immunosuppressants
IV (Vyvgart) or subcutaneous with hyaluronidase (Vyvgart Hytrulo)
Weekly infusion in 4-week cycles, or weekly SC injection
Headache, infection, and injection-site reactions; monitor for hypersensitivity
First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle.
immune-mediated myopathies, particularly those driven by IgG autoantibodies, although evidence remains sparse and preliminary
Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores.
Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal.
구조화 데이터
Human, cynomolgus
~3–4 days, but the IgG-lowering effect outlasts plasma exposure
Total IgG reduction, anti-AChR titer, MG-ADL change
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (generalized myasthenia gravis)
APPROVAL · 2021년 12월
Vyvgart Hytrulo subcutaneous formulation
APPROVAL · 2023년 6월
CIDP indication
APPROVAL · 2024년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
argenx
분석
큐레이션 브리핑
경쟁 포지션: First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
기전. Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FcRn (neonatal Fc receptor)
Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy
US, EU, JP
Approved
vyvgart · efgartigimod · Vyvgart · Vyvgart Hytrulo · ARGX-113 · efgartigimod alfa-fcab
2026-09-10
Data Confidence · High
Development Signal · Established
Engineered human IgG1 Fc fragment
ABDEG mutations give high-affinity, pH-independent FcRn binding that outcompetes endogenous IgG
Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression.
구조화 데이터
Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression.
Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal.
Engineered human IgG1 Fc fragment
FcRn (neonatal Fc receptor) · Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores.
Headache, infection, and injection-site reactions; monitor for hypersensitivity
First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
AChR-antibody-positive gMG; adults with CIDP
After acetylcholinesterase inhibitors and steroids/immunosuppressants
IV (Vyvgart) or subcutaneous with hyaluronidase (Vyvgart Hytrulo)
Weekly infusion in 4-week cycles, or weekly SC injection
Headache, infection, and injection-site reactions; monitor for hypersensitivity
First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab.
Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle.
immune-mediated myopathies, particularly those driven by IgG autoantibodies, although evidence remains sparse and preliminary
Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores.
Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal.
구조화 데이터
Human, cynomolgus
~3–4 days, but the IgG-lowering effect outlasts plasma exposure
Total IgG reduction, anti-AChR titer, MG-ADL change
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (generalized myasthenia gravis)
APPROVAL · 2021년 12월
Vyvgart Hytrulo subcutaneous formulation
APPROVAL · 2023년 6월
CIDP indication
APPROVAL · 2024년 6월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.